NEWS

As the United States recently marked its 250th anniversary, the occasion offered more than an opportunity to celebrate the nation’s achievements. It challenged us to reflect on one of the most enduring forces behind American progress: the conviction that discovery expands the boundaries of possibility, and that people who pursue bold ideas with persistence and purpose can fundamentally transform human life. That belief has never existed solely as an ideal. It has come to li

We Work For Health's Executive Director Dan Leonard recently sat down with Kelly Anderson, the Vice President of International Policy at the U.S. Chamber of Commerce’s Global Innovation Policy Center, to discuss the consequences of pharmaceutical price controls in Europe and why the U.S. should avoid making those same mistakes. As policymakers in Washington consider policies such as MFN price controls, Anderson provides a timely and analytical perspective on what's at stake f

We Work For Health Executive Director Dan Leonard issued the following statement in response to the United States Trade Representative’s Section 301 investigation into Germany's pharmaceutical pricing policies. “The USTR’s Section 301 investigation underscores the growing impact of Germany’s harmful pharmaceutical pricing policies on American patients, workers, and innovators. By keeping prices artificially below market value, Germany and other countries shift the bulk of t

WWFH recently partnered with Life Sciences Pennsylvania (LSPA) and the Council for Innovation Promotion (C4IP) to convene a roundtable with Rep. Madeleine Dean and leaders from across the life sciences sector at Rockland Immunochemicals, just outside the Philadelphia area. Pennsylvania plays a critical role in the nation’s innovation economy – supporting more than 262,350 jobs, including 56,086 direct roles, and generated approximately $85.2 billion in economic output in 20

We Work For Health Executive Director Dan Leonard sent a letter to Senate HELP Committee members ahead of a June 17 mark-up of legislation that will have broad implications for U.S. innovation, patient access and national security. Lawmakers were urged to reject proposals that could expose sensitive IP, increase litigation, undermine patent certainty, and weaken the innovation ecosystem. To learn more about the importance of IP protections, please see the following resources

Drug affordability continues to draw attention from policymakers, patients, employers and advocates – with intellectual property (IP) increasingly at the center of the debate. A recent Senate Judiciary hearing, Medicines and IP: Balancing Innovation and Access, brought critical attention to the ongoing debate. During the hearing, Ranking Member Hank Johnson (D-GA) spoke to the importance of patents: "Our nation's founders understood that when inventors are rewarded for their

On June 9, We Work For Health hosted a webinar convening leaders across business, venture capital, legal and innovation sectors to examine how drug pricing proposals – such as Most Favored Nation policies – could impact U.S. biomedical innovation, investment and future patient access to medicines. Panelists emphasized that U.S. biomedical innovation depends on a fragile ecosystem – where sustained investment, long development timelines and high failure rates require policy

America's global pharmaceutical edge is not as secure as many might think, and the data makes that increasingly clear. America's innovation ecosystem relies on robust policy that supports the full drug development process – from intellectual property and investment to research, development, and manufacturing. According to a recent report by the American Action Forum, China has surpassed the United States as the world's largest funder of R&D when measured on an international